The N‐terminal domain of gasdermin D induces liver fibrosis by reprogrammed lipid metabolism by Xue Wang, Chunyou Ning, Xingyi Cheng, Zhengzhong Wu, Dongbo Wu, Xuemei Ding, Cunxiang Ju, Zhihang Zhou, Lingfeng Wan, Wei Zhao, Peiliang Shi

Get full text

Sex-Specific Differences in the Pathophysiology of Hypertension by Hannah Zhang, Pawan K. Singal, Amir Ravandi, Inna Rabinovich-Nikitin

“…This adipose tissue subsequently produces anti-inflammatory effects and inhibits metabolic dysfunction-associated fatty liver disease (MAFLD) and RAS activation, ultimately leading to decreased levels of hypertension in pre-menopausal females. …”
Get full text

Relationship of Circulating Fetuin-A Levels with Body Size and Metabolic Phenotypes by Hye Soo Chung, Hyun Jung Lee, Soon Young Hwang, Ju-Hee Choi, Hye Jin Yoo, Ji A. Seo, Sin Gon Kim, Nan Hee Kim, Dong Seop Choi, Sei Hyun Baik, Kyung Mook Choi

“…Although nonalcoholic fatty liver disease (NAFLD) is strongly associated with obesity and metabolic syndrome, the relationship between these phenotypes and fetuin-A, a representative hepatokine, has not been explored. …”
Get full text

Principles of effective out-patient diagnostics of diffuse liver diseases by Komova A. G., M. V. Mayevskaya, V. T. Ivashkin

“…Prevalence of diffuse liver diseases in the studied sample (n=4768) was following: non-alcoholic fatty liver disease —7,4% (n=352), alcohol-induced liver disease — 6,9% (n=329), hepatitis C — 6,7% (n=322), hepatitis B — 1,9% (n=91), drug-induced liver disease — 0,82% (n=39), cholestatic liver diseases — 0,69 % (n=33), autoimmune hepatitis — 0,78% (n=37), others — 5,4% (n=258). …”
Get full text

Comparison of glimepiride and linagliptin in the treatment of non-alcoholic hepatic disease with type 2 diabetes mellitus by Feng Tian, Yali Guo, Liping Zhou, Qunying Yao, Xiaoyan Liang, Jiaxin Lu, Aiping He, Jie Shen

“…Introduction Nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) is associated with severe clinical outcomes. …”
Get full text

Apoptosis in the liver of male <em>db/db</em> mice during the development of obesity and type 2 diabetes by S. V. Michurina, I. Yu. Ishchenko, S. A. Arkhipov, M. A. Cherepanova, D. V. Vasendin, E. L. Zavjalov

“…Obesity and diabetes mellitus are known to lead to the development of metabolic syndrome and non-alcoholic fatty liver disease (NAFLD). The mechanisms of programmed cell death are actively involved in maintaining cellular homeostasis along development of NAFLD. …”
Get full text

The causal relationship of cigarette smoking to metabolic disease risk and the possible mediating role of gut microbiota by Jingda Zhang, Lin Hou, Shanxiang Lei, Yan Li, Guogang Xu

“…Emerging evidence suggests that cigarette smoking contributes to a range of pathological metabolic injuries, including diabetes and nonalcoholic fatty liver disease (NAFLD). The impact of gut microbiota on metabolic health and diseases has been observed, but the causality remains uncertain. …”
Get full text

Visfatin Induces Inflammation and Insulin Resistance via the NF-κB and STAT3 Signaling Pathways in Hepatocytes by Yu Jung Heo, Sung-E Choi, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Yup Kang, Kwan Woo Lee, Hae Jin Kim

“…Insulin resistance and inflammation are the principal pathogeneses of nonalcoholic fatty liver disease (NAFLD), but the relationship, if any, between visfatin and NAFLD remains unclear. …”
Get full text

Metallothionein 1B attenuates inflammation and hepatic steatosis in MASH by inhibiting the AKT/PI3K pathway by Canghai Guan, Xinlei Zou, Wujiang Shi, Jianjun Gao, Chengru Yang, Yifei Ge, Zhaoqiang Xu, Shaowu Bi, Xiangyu Zhong

“…Metabolic dysfunction–associated steatohepatitis (MASH) is a severe form of metabolic dysfunction–associated fatty liver disease metabolic dysfunction-associated steatohepatitis , characterized by hepatic steatosis, inflammation, and fibrosis. …”
Get full text

Cardiovascular Profile and Cardiovascular Imaging After Bariatric Surgery: A Narrative Review by Mihaela Toader, Liliana Gheorghe, Costin Chirica, Ionuț-Alexandru Ghicu, Sabina-Ioana Chirica, Andreea Isabela Mazga, Danisia Haba, Mădălina Maxim, Ancuța Andreea Miler, Daniela Crișu, Mihai Ștefan Cristian Haba, Daniel Vasile Timofte

“…<i>Materials and Methods</i>: The patients eligible for BaS commonly suffer from multiple chronic conditions, including type 2 diabetes, obstructive sleep apnea, cardiovascular diseases, and non-alcoholic fatty liver disease. Additionally, obesity contributes to an increased probability of developing certain types of cancer, osteoarthritis, urinary incontinence, and chronic kidney disease. …”
Get full text

Large annotated ultrasound dataset of non-alcoholic fatty liver from Saudi hospitals for analysis and applicationsOpen Science framework or (OSF) by Fahad Alshagathrh, Mahmood Alzubaidi, Khalid Alswat, Ali Aldhebaib, Bushra Alahmadi, Meteb Alkubeyyer, Abdulaziz Alosaimi, Amani Alsadoon, Maram Alkhamash, Jens Schneider, Mowafa Househ

“…This study presents a comprehensive ultrasound image dataset for Non-Alcoholic Fatty Liver Disease (NAFLD), addressing the critical need for standardized resources in AI-assisted diagnosis. …”
Get full text

The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights by Zhuo Huang, Zhuo Huang, Qinyan Yao, Qinyan Yao, Shuang Ma, Shuang Ma, Jinjie Zhou, Jinjie Zhou, Xiaoxuan Wang, Xiaoxuan Wang, Qingguo Meng, Qingguo Meng, Yaxin Liu, Yaxin Liu, Zihan Yu, Zihan Yu, Xin Chen, Xin Chen

“…Dysbiosis of the gut microbiota has been linked to metabolic disorders such as type 2 diabetes, obesity, metabolic-associated fatty liver disease (MAFLD) and metabolic heart disease. …”
Get full text

A Network Pharmacology-Based Approach for Exploring Key Active Compounds and Pharmacological Mechanisms of Tangshen Formula for Treatment of Diabetic Nephropathy by Weie Zhou, Xuefeng Zhou, Yuan Zhang, Yuyang Wang, Wenjie Wu, Haojun Zhang, Tingting Zhao, Liang Peng, Hailing Zhao, Ping Li

“…The quercetin, naringenin, kaempferol, and isorhamnetin as key active compounds and the PI3K-Akt signaling pathway, TNF signaling pathway, nonalcoholic fatty liver disease (NAFLD), focal adhesion, rap1 signaling pathway, T cell receptor signaling pathway, MAPK signaling pathway, and insulin resistance as the key molecular mechanisms play important roles in TSF treating DN. …”
Get full text

Effects of ultra-processed foods on the liver: insights from gut microbiome and metabolomics studies in rats by Liping Shi, Zhuoyuan Li, Xiaojun Ma, Junru Wang, Yueping Wu, Yongbin Zhu, Yanrong Wang, Yue Yang, Minxiu Luo, Jiangping Li, Xian Sun, Xian Sun, Shulan He, Shulan He

“…PurposeHigh consumption of Ultra-processed foods (UPF) have been identified as a potential risk factor for Non-alcoholic fatty liver disease (NAFLD). Nevertheless, there is limited empirical evidence regarding the impact of UPF, which are typical combination of processed foods, on liver health through alterations in gut microbiota and metabolic processes. …”
Get full text

Comparative Efficacy of NAFLD Therapies and Biomarker Associations: A Meta-Analysis Based on Liver Fat Content by Haoxiang Zhu, Ling Xu, Yinhua Lv, Juan Yang, Jihan Huang, Qingshan Zheng, Guang Ji, Lujin Li

“…Background and Aims: This study aims to conduct a comprehensive quantitative analysis of various nonalcoholic fatty liver disease (NAFLD) therapeutics, utilizing magnetic resonance (MR)-detected liver fat content (LFC) as the efficacy endpoint, and to identify biomarkers correlated with changes in LFC based on published literature. …”
Get full text

The Predictive Value of Time-Varying Noninvasive Scores on Long-Term Prognosis of NAFLD in South Korea by Sung Won Chung, Min Kyung Park, Xiao Zhang, Tongtong Wang, Thomas Jemielita, Gail Fernandes, Samuel S. Engel, Heejoon Jang, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim

“…This study aimed to examine whether repeated measurements on noninvasive fibrosis scores during follow-up improve long-term nonalcoholic fatty liver disease (NAFLD) outcome prediction. Methods. …”
Get full text

The serum hepcidin and the hepcidin/ferritin ratio in NAFLD: a systematic review and meta-analysis by Jingmin Song, Heqing Wang, Xiaolian Gao, Fen Yang, Xinhong Zhu, Guiyuan Qiao, Ting Gan, Junxiu Tao

“…Abstract Background Non-alcoholic fatty liver disease (NAFLD) is a spectrum of chronic liver diseases characterized by hepatic steatosis exceeding 5% in the absence of alcohol and other liver-damaging factors. …”
Get full text

Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH) by Zobair M. Younossi, Maria Stepanova, Issah Younossi, Andrei Racila

“…Methods: From our non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) database, patients who met the definition of MASH according to the new criteria were selected. …”
Get full text

Unveiling the novel role of circadian rhythms in sepsis and septic shock: unexplored implications for chronotherapy by Stewart D. Ramsay, Stewart D. Ramsay, Stewart D. Ramsay, Marni A. Nenke, Marni A. Nenke, Emily J. Meyer, Emily J. Meyer, David J. Torpy, David J. Torpy, Richard L. Young, Richard L. Young, Richard L. Young, Richard L. Young

“…These disruptions misalign external cues to body processes and contribute to diseases such as obesity and non-alcoholic fatty liver disease. They also exacerbate pre-existing health issues, such as depression and inflammatory bowel disease. …”
Get full text

Albumin Binding Function: The Potential Earliest Indicator for Liver Function Damage by Penglei Ge, Huayu Yang, Jingfen Lu, Wenjun Liao, Shunda Du, Yingli Xu, Haifeng Xu, Haitao Zhao, Xin Lu, Xinting Sang, Shouxian Zhong, Jiefu Huang, Yilei Mao

“…Currently there is no indicator that can evaluate actual liver lesion for early stages of viral hepatitis, nonalcoholic fatty liver disease (NAFLD), and cirrhosis. Aim of this study was to investigate if albumin binding function could better reflect liver function in these liver diseases. …”
Get full text